• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.460 -0.070 (-1.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,554
Open 3.530
Bid (Size) 3.350 (1,800)
Ask (Size) 3.600 (100)
Prev. Close 3.530
Today's Range 3.410 - 3.589
52wk Range 2.550 - 6.118
Shares Outstanding 11,184,423
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
January 20, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
January 20, 2026
From Lantern Pharma Inc.
Via Business Wire

Performance

YTD
+11.3%
+11.3%
1 Month
+3.6%
+3.6%
3 Month
-15.2%
-15.2%
6 Month
-18.3%
-18.3%
1 Year
-17.0%
-17.0%

More News

Read More
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
January 12, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
January 12, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
December 27, 2025
Via ACCESS Newswire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
December 03, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
December 03, 2025
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
November 13, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 13, 2025
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
November 13, 2025
Via Benzinga
News headline image
Lantern Pharma Earnings Preview ↗
November 12, 2025
Via Benzinga
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
November 10, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
November 08, 2025
Via ACCESS Newswire
News headline image
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
November 07, 2025
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
November 06, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
November 06, 2025
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
October 30, 2025
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress
October 28, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
October 28, 2025
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30
October 24, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
October 24, 2025
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership
October 22, 2025
Via Investor Brand Network
Topics Artificial Intelligence
MissionIRNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment
October 14, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
October 10, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
October 03, 2025
Via ACCESS Newswire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 3.460
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 01/23/26 04:00 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 38.70M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 39M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap